Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-27 7:01 pm Purchase | 13D | Poseida Therapeutics Inc. PSTX | Pentwater Capital Management LP | 8,625,000 8.800% | 3,657,773 (+73.64%) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Poseida Therapeutics Inc. PSTX | BlackRock Inc. BLK | 5,123,969 5.300% | 0 (Unchanged) | View |
| 2024-10-22 3:24 pm Purchase | 13G | Poseida Therapeutics Inc. PSTX | BlackRock Inc. BLK | 5,123,969 5.300% | 296,730 (+6.15%) | View |
| 2024-06-07 1:30 pm Sale | 13G | Poseida Therapeutics Inc. PSTX | BlackRock Inc. BLK | 4,827,239 4.970% | -203,934 (-4.05%) | View |
| 2024-05-08 4:01 pm Sale | 13G | Poseida Therapeutics Inc. PSTX | NOVARTIS PHARMA AG | 0 0.000% | -5,908,089 (Position Closed) | View |
| 2024-02-09 09:28 am Purchase | 13G | Poseida Therapeutics Inc. PSTX | FMR LLC | 14,343,665 14.999% | 1,451,258 (+11.26%) | View |
| 2024-01-31 2:08 pm Purchase | 13G | Poseida Therapeutics Inc. PSTX | BlackRock Inc. BLK | 5,031,173 5.300% | 5,031,173 (New Position) | View |
| 2023-08-14 4:41 pm Purchase | 13D | Poseida Therapeutics Inc. PSTX | Astellas US LLC | 8,333,333 8.700% | 8,333,333 (New Position) | View |
| 2023-02-09 12:31 pm Purchase | 13G | Poseida Therapeutics Inc. PSTX | FMR LLC | 12,892,407 14.999% | 3,516,466 (+37.51%) | View |
| 2022-04-25 4:30 pm Unchanged | 13D | Poseida Therapeutics Inc. PSTX | Pentwater Capital Management LP | 4,967,227 7.940% | 0 (Unchanged) | View |
| 2022-02-09 10:24 am Purchase | 13G | Poseida Therapeutics Inc. PSTX | FMR LLC | 9,375,941 14.999% | 102,940 (+1.11%) | View |
| 2021-02-12 4:24 pm Purchase | 13G | Poseida Therapeutics Inc. PSTX | NOVARTIS PHARMA AG | 5,908,089 9.600% | 5,908,089 (New Position) | View |
| 2021-02-08 10:31 am Purchase | 13G | Poseida Therapeutics Inc. PSTX | FMR LLC | 9,273,001 14.999% | 619 (+0.01%) | View |
| 2021-02-03 06:15 am Purchase | 13G | Poseida Therapeutics Inc. PSTX | Malin Life Sciences Holdings Ltd | 9,188,125 14.900% | 9,188,125 (New Position) | View |
| 2020-12-28 4:05 pm Purchase | 13D | Poseida Therapeutics Inc. PSTX | Pentwater Capital Management LP | 4,967,227 8.030% | 4,967,227 (New Position) | View |
| 2020-08-10 09:25 am Purchase | 13G | Poseida Therapeutics Inc. PSTX | FMR LLC | 9,272,382 14.999% | 9,272,382 (New Position) | View |